Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Doxorubicin × Tumor-Agnostic × Clear all

Phase

Phase 1 6 Phase 2 3 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 49 Breast 21 Sarcoma 14 Other hematologic neoplasm 10 Gynecologic 6 Gastrointestinal 5 Plasma cell 4 Dermatologic 4 Genitourinary 3 Head & Neck 2 CNS 2 Tumor-Agnostic 1 Thoracic 1 Other solid neoplasm 1 Myeloid 1 Endocrine 1 Classical hematology 1

Conditions

Interventions

pembrolizumab 17 Nivolumab 15 Gemcitabine 8 Carboplatin 8 Capecitabine 8 Cisplatin 7 Paclitaxel 6 Ipilimumab 6 Irinotecan 5 Cyclophosphamide 5 avelumab 4 atezolizumab 4 Trastuzumab 4 Fluorouracil 4 Docetaxel 4 Cetuximab 4 Bevacizumab 4 trametinib 3 Specimen Handling 3 Pemetrexed 3 Leucovorin 3 Everolimus 3 Biopsy 3 urelumab 2 toripalimab 2 tislelizumab 2 spartalizumab 2 ribociclib 2 repotrectinib 2 regorafenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00124956 2017-09-11

Doxorubicin Pharmacokinetic (PK) Study

Boston Children's Hospital

Phase 1/2 Withdrawn

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡